Anti-inflammatory agents can effectively and safely curb major depressive symptoms

Anti-inflammatory agents, such as aspirin/paracetamol, statins, and antibiotics, can safely and effectively curb the symptoms of major depression, finds a pooled analysis of the available evidence, published online in the Journal of Neurology Neurosurgery & Psychiatry. And the effects are even stronger when these agents are added on to standard antidepressant treatment, the results show. Around a third of people […]

Continue reading »

Major data release set for early 2019 as recruitment wraps up for nation’s largest adolescent brain study

Research teams all across the globe are eagerly awaiting a major release of data from the largest study ever attempted on the adolescent brain. FIU is one of 21 sites studying nearly 11,874 participants collectively, including 2,100 twins or triplets. Researchers will follow the children, currently between the ages of 9 and 10, through young adulthood. Recruitment for participants wrapped […]

Continue reading »

Major response to immunotherapy in early-stage mismatch repair deficient colon cancer

Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100 percent of early-stage colon cancers with mismatch repair deficiencies, according to results reported at ESMO 2018 from the first exploratory phase II trial to investigate this approach. Restoring patients’ immune response against cancer cells with checkpoint inhibitors is an established treatment […]

Continue reading »

Researchers call for major re-think on sun safety

Most Australians are familiar with the ‘slip, slop, slap’ message, but new research suggests we’re not taking sun safety seriously enough. Currently, health agencies recommend that sun protection is used when the UV Index – which measures the intensity of UV radiation – is three or higher. But researchers from The Australian National University (ANU) and New Zealand’s National Institute […]

Continue reading »

Switching to certain antidiabetic drugs linked to increased risk of major complications

For people with type 2 diabetes, switching to sulfonylurea drugs to control blood sugar levels is associated with an increased risk of complications compared with staying on the drug metformin, finds a study in The BMJ today. As such, the researchers say that continuing metformin when introducing sulfonylureas is safer than switching. Metformin is a “first-line” therapy (the first drug […]

Continue reading »

Older age tied to poorer course of major depressive disorder

(HealthDay)—Older age is associated with poorer course of major depressive disorder (MDD), according to a study published online June 7 in The Lancet Psychiatry. Roxanne Schaakxs, Ph.D., from VU University Medical Center in Amsterdam, and colleagues obtained data for 1,042 participants with MDD at baseline, who had data available at baseline and two-year follow-up. The primary outcome was the two-year […]

Continue reading »

Relapse in major depression linked to brain cortical changes

(HealthDay)—For patients with major depressive disorder (MDD), relapse is associated with brain cortical changes over two years, according to a study published online March 28 in JAMA Psychiatry. Dario Zaremba, from the University of Münster in Germany, and colleagues conducted a longitudinal case-control study involving patients with acute MDD at baseline and healthy controls. Participants were subdivided into groups with […]

Continue reading »